{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:30Z","timestamp":1786994010524,"version":"build-2736575974"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":161,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.mcpro.2021.100112","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T07:12:20Z","timestamp":1623481940000},"page":"100112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases"],"prefix":"10.1016","volume":"20","author":[{"given":"Keira E.","family":"Mahoney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-3539","authenticated-orcid":false,"given":"Jeffrey","family":"Shabanowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2021.100112_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.1546328","article-title":"Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry","volume":"255","author":"Hunt","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2021.100112_bib2","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcpro.2021.100112_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.mcpro.2021.100112_bib4","first-page":"1","article-title":"Tumor neoantigens: From basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3389\/fcell.2020.00728","article-title":"Progress in neoantigen targeted cancer immunotherapies","volume":"8","author":"Han","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mcpro.2021.100112_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2021.100112_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cancers12030535","article-title":"Mass spectrometry-based identification of MHC-associated peptides","volume":"12","author":"Kote","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2021.100112_bib8","first-page":"5144","article-title":"The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene","volume":"58","author":"Hogan","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1074\/mcp.TIR119.001641","article-title":"Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA class I ligands","volume":"19","author":"Solleder","year":"2020","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100112_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14789450.2020.1845147","article-title":"Using phosphoproteomics and next generation sequencing to discover novel therapeutic targets in patient antibodies","volume":"17","author":"Zeneyedpour","year":"2020","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100112_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006098","article-title":"Signal transduction in cancer","volume":"5","author":"Sever","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.mcpro.2021.100112_bib12","series-title":"Biochemistry","first-page":"400","author":"Berg","year":"2007"},{"key":"10.1016\/j.mcpro.2021.100112_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbamcr.2018.08.020","article-title":"Targeting PP2A in cancer: Combination therapies","volume":"1866","author":"Mazhar","year":"2019","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/ijmm.2017.3036","article-title":"The crucial role of protein phosphorylation in cell signalingand its use as targeted therapy (review)","volume":"40","author":"Ardito","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.mcpro.2021.100112_bib15","doi-asserted-by":"crossref","first-page":"659649","DOI":"10.1155\/2012\/659649","article-title":"Phosphatases: The new brakes for cancer development?","volume":"2012","author":"Zhang","year":"2012","journal-title":"Enzyme Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib16","series-title":"Target peptides for cancer therapy and diagnostics","author":"Hunt","year":"2019"},{"key":"10.1016\/j.mcpro.2021.100112_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-54700-2","article-title":"Murine xenograft bioreactors for human immunopeptidome discovery","volume":"9","author":"Heather","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcpro.2021.100112_bib18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/nprot.2015.086","article-title":"Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry","volume":"10","author":"Abelin","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.mcpro.2021.100112_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2021.100112_bib20","doi-asserted-by":"crossref","first-page":"10275","DOI":"10.1073\/pnas.90.21.10275","article-title":"Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells","volume":"90","author":"Henderson","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2021.100112_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I\u2013associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mcpro.2021.100112_bib22","series-title":"Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies","author":"Hunt","year":"2020"},{"key":"10.1016\/j.mcpro.2021.100112_bib23","series-title":"Phosphopeptides as melanoma vaccines","author":"Topalian","year":"2016"},{"key":"10.1016\/j.mcpro.2021.100112_bib24","doi-asserted-by":"crossref","first-page":"14889","DOI":"10.1073\/pnas.0604045103","article-title":"Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy","volume":"103","author":"Zarling","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2021.100112_bib25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ni.1660","article-title":"Phosphorylation-dependent interaction between antigenic peptides and MHC class I: A molecular basis for the presentation of transformed self","volume":"9","author":"Mohammed","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.mcpro.2021.100112_bib26","doi-asserted-by":"crossref","first-page":"54160","DOI":"10.18632\/oncotarget.16952","article-title":"The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status","volume":"8","author":"Mohammed","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcpro.2021.100112_bib27","series-title":"Class I MHC phosphopeptides for cancer immunotherapy and diagnosis","author":"Hunt","year":"2013"},{"key":"10.1016\/j.mcpro.2021.100112_bib28","article-title":"MHC-restricted phosphopeptide antigens: Preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma","volume":"8","author":"Engelhard","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2021.100112_bib29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/febs.13573","article-title":"All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase","volume":"283","author":"Sangodkar","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.mcpro.2021.100112_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbacli.2016.08.002","article-title":"The broken \u201coff\u201d switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance","volume":"6","author":"Ruvolo","year":"2016","journal-title":"BBA Clin."},{"key":"10.1016\/j.mcpro.2021.100112_bib31","first-page":"197","article-title":"Cellular inhibitors of protein phosphatase PP2A in cancer","volume":"23","author":"Haesen","year":"2012","journal-title":"Biomed. Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib32","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: A target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib33","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbadis.2011.07.001","article-title":"PP2A targeting by viral proteins: A widespread biological strategy from DNA\/RNA tumor viruses to HIV-1","volume":"1812","author":"Guergnon","year":"2011","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.mcpro.2021.100112_bib34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/iub.1067","article-title":"Endogenous inhibitor proteins that connect Ser\/Thr kinases and phosphatases in cell signaling","volume":"64","author":"Eto","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.mcpro.2021.100112_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2016.00078","article-title":"Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia","volume":"6","author":"Arriazu","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/10409238.2016.1143913","article-title":"PP2A as a master regulator of the cell cycle","volume":"51","author":"Wlodarchak","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.mcpro.2021.100112_bib37","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/ijms18081776","article-title":"The retinoblastoma (RB) tumor suppressor: Pushing back against genome instability on multiple fronts","volume":"18","author":"V\u00e9lez-Cruz","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib38","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2021.100112_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.biochi.2003.09.004","article-title":"Serine\/threonine protein phosphatases PP1 and PP2A are key players in apoptosis","volume":"85","author":"Garcia","year":"2003","journal-title":"Biochimie"},{"key":"10.1016\/j.mcpro.2021.100112_bib40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molcel.2009.02.015","article-title":"From promiscuity to precision: Protein phosphatases get a makeover","volume":"33","author":"Virshup","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.mcpro.2021.100112_bib41","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.celrep.2019.07.067","article-title":"PP1 and PP2A use opposite phospho-dependencies to control distinct processes at the kinetochore","volume":"28","author":"Smith","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.mcpro.2021.100112_bib42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.tibs.2007.12.004","article-title":"PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)","volume":"33","author":"Janssens","year":"2008","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib43","doi-asserted-by":"crossref","first-page":"13856","DOI":"10.1074\/jbc.272.21.13856","article-title":"Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin","volume":"272","author":"Favre","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2021.100112_bib44","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/cancers7020648","article-title":"PP2A: The wolf in sheep\u2019s clothing?","volume":"7","author":"Kiely","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.mcpro.2021.100112_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbcan.2008.05.005","article-title":"Protein phosphatase 2A regulatory subunits and cancer","volume":"1795","author":"Eichhorn","year":"2009","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.mcpro.2021.100112_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph0209s60","article-title":"The human kinome and kinase inhibition","author":"Duong-Ly","year":"2013","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.mcpro.2021.100112_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015411","article-title":"Identifying human kinase-specific protein phosphorylation sites by integrating heterogeneous information from various sources","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2021.100112_bib48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.gde.2004.12.004","article-title":"PP2A: The expected tumor suppressor","volume":"15","author":"Janssens","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.mcpro.2021.100112_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2004.07.009","article-title":"Species- and cell type-specific requirements for cellular transformation","volume":"6","author":"Rangarajan","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mcpro.2021.100112_bib50","first-page":"2327","article-title":"Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: Implications for prognosis","volume":"9","author":"Wang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/22780","article-title":"Creation of human tumour cells with defined genetic elements","volume":"400","author":"Hahn","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.mcpro.2021.100112_bib52","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1074\/jbc.RA119.011265","article-title":"Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1","volume":"295","author":"Kauko","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2021.100112_bib53","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","article-title":"Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: An open-label, dose escalation, first-in-human, phase I trial","volume":"23","author":"Chung","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib54","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2011.04.031","article-title":"Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein","volume":"122","author":"Liu","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib55","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.2011.346","article-title":"Prognostic role of CIP2A expression in serous ovarian cancer","volume":"105","author":"B\u00f6ckelman","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2021.100112_bib56","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-08-3283","article-title":"CIP2A is associated with human breast cancer aggressivity","volume":"15","author":"C\u00f4me","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib57","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1245\/s10434-010-1313-8","article-title":"CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis","volume":"18","author":"Dong","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib58","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Lucas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mcpro.2021.100112_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human malignancies","volume":"130","author":"Junttila","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2021.100112_bib60","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","article-title":"The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A","volume":"271","author":"Li","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2021.100112_bib61","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1021\/bi960581y","article-title":"Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A","volume":"35","author":"Li","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.mcpro.2021.100112_bib62","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1111\/febs.14617","article-title":"Targeted therapies don\u2019t work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back","volume":"285","author":"Westermarck","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.mcpro.2021.100112_bib63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1078-0432.CCR-14-0724","article-title":"Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer","volume":"21","author":"Crist\u00f3bal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib64","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: Statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2021.100112_bib65","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0959-437X(01)00265-9","article-title":"The role of p53 and pRB in apoptosis and cancer","volume":"12","author":"Hickman","year":"2002","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.mcpro.2021.100112_bib66","first-page":"195","article-title":"Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways","volume":"1","author":"Zhao","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2013.00008","article-title":"Response to DNA damage: Why do we need to focus on protein phosphatases?","volume":"3","author":"Shimada","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.emboj.7601519","article-title":"A\u00a0specific PP2A regulatory subunit, B56\u03b3, mediates DNA damage-induced dephosphorylation of p53 at Thr55","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.mcpro.2021.100112_bib69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj.cdd.4400323","article-title":"pRb and the Cdks in apoptosis and the cell cycle","volume":"5","author":"Kasten","year":"1998","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.mcpro.2021.100112_bib70","doi-asserted-by":"crossref","first-page":"20160274","DOI":"10.1098\/rstb.2016.0274","article-title":"Viral hepatitis and liver cancer","volume":"372","author":"Ringelhan","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib71","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1371\/journal.ppat.0030139","article-title":"Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein","volume":"3","author":"Munakata","year":"2007","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.mcpro.2021.100112_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13046-015-0255-1","article-title":"Hepatitis C virus core protein modulates pRb2\/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation","volume":"34","author":"Mileo","year":"2015","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062581","article-title":"Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm","volume":"8","author":"Bittar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2021.100112_bib74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.4434","article-title":"The direct and indirect roles of HBV in liver cancer: Prospective markers for HCC screening and potential therapeutic targets","volume":"235","author":"Ringelhan","year":"2015","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.mcpro.2021.100112_bib75","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/0008-5472.CAN-07-0529","article-title":"Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclinD1-CDK 4\/6-pRb-E2F1 pathway","volume":"67","author":"Jin","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib76","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/v9080230","article-title":"Interference of apoptosis by hepatitis B virus","volume":"9","author":"Lin","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.mcpro.2021.100112_bib77","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: A synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.mcpro.2021.100112_bib78","doi-asserted-by":"crossref","first-page":"20160273","DOI":"10.1098\/rstb.2016.0273","article-title":"Oncogenic human papillomaviruses","volume":"372","author":"McBride","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib79","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/JVI.78.5.2620-2626.2004","article-title":"Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11","volume":"78","author":"Oh","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.mcpro.2021.100112_bib80","first-page":"1","article-title":"Role of HR-HPVs E6 and E7 oncoproteins in cervical carcinogenesis","volume":"10","author":"Gariglio","year":"2016","journal-title":"J.\u00a0Mol. Genet. Med."},{"key":"10.1016\/j.mcpro.2021.100112_bib81","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.virol.2013.04.013","article-title":"The papillomavirus E7 proteins","volume":"445","author":"Roman","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.mcpro.2021.100112_bib82","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.18632\/oncotarget.2127","article-title":"Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands","volume":"5","author":"De","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcpro.2021.100112_bib83","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ijc.29431","article-title":"Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers","volume":"138","author":"Khanna","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.mcpro.2021.100112_bib84","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1073\/pnas.89.10.4442","article-title":"Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses","volume":"89","author":"Heck","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2021.100112_bib85","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2013.04.026","article-title":"Papillomavirus E6 oncoproteins","volume":"445","author":"Vande Pol","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.mcpro.2021.100112_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02234-14","article-title":"Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B","volume":"5","author":"Vieira","year":"2014","journal-title":"MBio"},{"key":"10.1016\/j.mcpro.2021.100112_bib87","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0092-8674(91)90529-8","article-title":"Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation","volume":"67","author":"Crook","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2021.100112_bib88","doi-asserted-by":"crossref","first-page":"20160266","DOI":"10.1098\/rstb.2016.0266","article-title":"Tumour virus epidemiology","volume":"372","author":"Lunn","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib89","doi-asserted-by":"crossref","first-page":"20160271","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-barr virus-associated lymphomas","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib90","doi-asserted-by":"crossref","first-page":"20160270","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.mcpro.2021.100112_bib91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr virus\u2013associated lymphomas","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib92","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1073\/pnas.0801053105","article-title":"EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes","volume":"105","author":"Kashuba","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2021.100112_bib93","doi-asserted-by":"crossref","first-page":"18562","DOI":"10.1073\/pnas.0503886102","article-title":"Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase","volume":"102","author":"Knight","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2021.100112_bib94","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/JVI.02408-08","article-title":"Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2","volume":"83","author":"Saha","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.mcpro.2021.100112_bib95","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1128\/JVI.02435-06","article-title":"Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A","volume":"81","author":"Garibal","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.mcpro.2021.100112_bib96","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/MMBR.00065-15","article-title":"HIV genome-wide protein associations: A review of 30 years of research","volume":"80","author":"Li","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.mcpro.2021.100112_bib97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/v8030067","article-title":"Remodeling of the host cell plasma membrane by HIV-1 Nef and Vpu: A strategy to ensure viral fitness and persistence","volume":"8","author":"Sugden","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.mcpro.2021.100112_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.18296","article-title":"Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants","volume":"5","author":"Greenwood","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.mcpro.2021.100112_bib99","doi-asserted-by":"crossref","first-page":"13099","DOI":"10.1038\/srep13099","article-title":"Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling","volume":"5","author":"Kauko","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcpro.2021.100112_bib100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/v12020244","article-title":"Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV","volume":"12","author":"Xu","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.mcpro.2021.100112_bib101","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1128\/JVI.07012-11","article-title":"The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein","volume":"86","author":"Bhardwaj","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.mcpro.2021.100112_bib102","first-page":"4620","article-title":"E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway","volume":"56","author":"Boyer","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib103","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.2537532","article-title":"The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product","volume":"243","author":"Dyson","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2021.100112_bib104","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virol.2005.10.015","article-title":"SARS coronavirus 7a protein blocks cell cycle progression at G0\/G1 phase via the cyclin D3\/pRb pathway","volume":"346","author":"Yuan","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.mcpro.2021.100112_bib105","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1074\/mcp.M400112-MCP200","article-title":"Quantitative analysis of severe acute respiratory syndrome (SARS)-associated coronavirus-infected cells using proteomic approaches: Implications for cellular responses to virus infection","volume":"4","author":"Jiang","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100112_bib106","article-title":"LxxIxE-like motif in spike protein of SARS-CoV-2 that is known to recruit the host PP2A-B56 phosphatase mimics Artepillin C, an immunomodulator, of Brazilian green propolis","author":"Maaroufi","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.mcpro.2021.100112_bib107","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/fon.10.37","article-title":"Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis","volume":"6","author":"Ding","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib108","first-page":"6350","article-title":"Coexpression of Helicobacter pylori\u2019s proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection","volume":"63","author":"De Luca","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1099\/jmm.0.014704-0","article-title":"Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK\/ERK pathways","volume":"59","author":"Zhao","year":"2010","journal-title":"J.\u00a0Med. Microbiol."},{"key":"10.1016\/j.mcpro.2021.100112_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrmicro.2016.171","article-title":"Collateral damage: Insights into bacterial mechanisms that predispose host cells to cancer","volume":"15","author":"Gagnaire","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.mcpro.2021.100112_bib111","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.7150\/jca.24048","article-title":"Association between Fusobacterium nucleatum and colorectal cancer: Progress and future directions","volume":"9","author":"Zhang","year":"2018","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.mcpro.2021.100112_bib112","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1126\/science.aal5240","article-title":"Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer","volume":"358","author":"Bullman","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2021.100112_bib113","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fonc.2019.00566","article-title":"Global investigations of fusobacterium nucleatum in human colorectal cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcpro.2021.100112_bib114","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","article-title":"Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u03b2-catenin signaling via its FadA adhesin","volume":"14","author":"Rubinstein","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mcpro.2021.100112_bib115","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1158\/1078-0432.CCR-16-1786","article-title":"Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis","volume":"22","author":"Yamamura","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2021.100112_bib116","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","article-title":"Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment","volume":"14","author":"Kostic","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.mcpro.2021.100112_bib117","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41467-020-16967-2","article-title":"Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression","volume":"11","author":"Parhi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2021.100112_bib118","doi-asserted-by":"crossref","first-page":"31802","DOI":"10.18632\/oncotarget.15992","article-title":"Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4\/P-PAK1 cascade","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcpro.2021.100112_bib119","doi-asserted-by":"crossref","first-page":"27677","DOI":"10.1074\/jbc.M114.565358","article-title":"Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces alzheimer-like abnormal hyperphosphorylation of Tau","volume":"289","author":"Arif","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2021.100112_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2014.00016","article-title":"Protein phosphatase 2A dysfunction in Alzheimer\u2019s disease","volume":"7","author":"Sontag","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.mcpro.2021.100112_bib121","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","article-title":"Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation","volume":"22","author":"Liu","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.mcpro.2021.100112_bib122","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0002-9440(10)62486-8","article-title":"Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer\u2019s disease","volume":"166","author":"Tanimukai","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mcpro.2021.100112_bib123","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1074\/mcp.M900001-MCP200","article-title":"Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients","volume":"8","author":"Fissolo","year":"2009","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.mcpro.2021.100112_bib124","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.4049\/jimmunol.136.11.4054","article-title":"Monoclonal antibody analysis of MHC expression in human brain biopsies: Tissue ranging from \u201chistologically normal\u201d to that showing different levels of glial tumor involvement","volume":"136","author":"Lampson","year":"1986","journal-title":"J.\u00a0Immunol."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947621000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947621000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:12:34Z","timestamp":1761527554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947621000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":124,"alternative-id":["S1535947621000840"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2021.100112","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2021.100112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100112"}}